Shares in Acorda Therapeutics (NSDQ:ACOR) dropped nearly -30% today after the FDA told the company that the new drug application for its inhaled Parkinson’s disease treatment is incomplete.
The FDA’s refusal to file letter surprised analysts. The note from the regulatory agency had to do with the date when the manufacturing site would be ready for inspection and a question about the submission of the drug master production record, Acorda said.
Get the full story at our sister site, Drug Delivery Business News.
The post Acorda shares plunge -30% after FDA refuses to review NDA appeared first on MassDevice.